



# BONE MARROW TRANSPLANTATION



Richard K. Burt  
H. Joachim Deeg  
Scott Thomas Lothian  
George W. Santos



CHAPMAN  
& HALL

LANDES  
BIOSCIENCE

Once upon a time there were three musketeers  
Known throughout the land for their good cheers  
Beauty was the first, so full of effervescent life  
to the lucky man would she become his wife  
Science was marveled as the eighth wonder  
His logic and wisdom were as clear as thunder  
Courage, a great horseman, would mount and ride  
For no one could stand in his stride  
Far and wide did they play  
And many an evil dragon did they slay

Then one day, beauty lay fallen  
Science and Courage were sullen  
Do not be sad, for it was not long  
In the future Beauty grew strong  
Next Science fell to his side  
And left alone was Courage to ride

With head and sword held high, he charged from the rear  
But an Achilles' heel did he also have to fear  
For he knew little of Cupid's arrow  
Soon it found him too, so long and narrow

May all children grow up and then once again be given the  
chance to re-live life through the eyes of their children and grand-  
children.

*Richard K. Burt, M.D.*

## 1.0 General

### 1.1 History of Bone Marrow Transplantation ..... 3

*George W. Santos*

Introduction .....	3
Early History .....	3
Acute Graft-Versus-Host Disease (aGVHD) .....	3
Tolerance .....	4
Chronic GVHD (cGVHD) .....	4
Transplant Preparative Regimens .....	4
Donors .....	4
Clinical Studies .....	6
Conclusion .....	7

### 1.2 Bone Marrow Transplantation Unit..... 8

*Philip L. McCarthy Jr., Lori A Williams*

Requirements.....	8
Outpatient Autologous BMT .....	12

### 1.3 Patient and Donor Evaluation ..... 14

*Lori A Williams, Philip L. McCarthy Jr.*

Introduction .....	14
Patient Evaluation .....	14
Prior or Outside Laboratory Tests .....	15
Requirements for HDCT.....	15
Financial Screening and Evaluation .....	18
Pretreatment Evaluation Parameters .....	18
Pretreatment Procedures .....	20
Donor Evaluation .....	21

### 1.4 Bone Marrow Transplantation from Unrelated Donors ..... 23

*James Gajewski, Richard Champlin*

Introduction .....	23
Unrelated Donor Registries .....	23
How to Become a Volunteer Donor .....	24
Unrelated Donor Search Process .....	24
Histocompatibility Considerations .....	25
Results of Unrelated Donor BMT .....	26

### 1.5 Costs of Care for Bone Marrow Transplantations for Malignant Hematopoietic Diseases..... 29

*Ilana Westerman, Charles Bennett*

Introduction .....	29
Welch Study.....	29
Viens-Bitker Study .....	30
Bennett Study .....	32
Itemized Charges for Bone Marrow Transplantation .....	35

## 2.0 Transplantation Procedures..... 39

*Suzanne G. Demko*

Bone Marrow Aspirate/Biopsy .....	39
Skin Biopsy .....	41
Bone Marrow Harvest .....	43
Bone Marrow Re-infusion .....	49
Peripheral Blood Stem Cell Collection .....	50

<b>3.0</b>	<b>Transfusion Medicine in Marrow and Blood Cell Transplantation</b>	
<b>3.1</b>	<b>Transfusions</b> .....	<b>54</b>
	<i>Michele Cottler-Fox</i>	
	Blood Donation .....	54
	Blood Components .....	54
	Storage of Blood Components .....	61
	Administration of Blood Products.....	61
	Transfusion Reactions .....	62
	Transfusion-Transmitted Diseases .....	64
	Special Considerations for Transfusion in the BMT Patient .....	64
<b>3.2</b>	<b>Hematopoietic Progenitor Stem Cells</b> .....	<b>69</b>
	<i>Michele Cottler-Fox</i>	
	Introduction .....	69
	Definition and Characterization of HPC .....	69
	Sources of HPC .....	70
	Separation of HPC (Enrichment).....	72
	Ex Vivo Expansion of HPC.....	73
	Clinical Results of Autologous Blood-Derived HPC Transplantation .....	73
	Clinical Results of Allogeneic Blood-Derived HPC Transplantation .....	75
<b>3.3</b>	<b>Purging of Bone Marrow and Peripheral Blood Stem Cells</b> ....	<b>76</b>
	<i>Ellen Areman, Chitra Rajagopal</i>	
	Introduction .....	76
	Purging of Autologous Marrow/Peripheral Blood Stem Cells .....	76
	Purging of Allogeneic Bone Marrow and Peripheral Blood Stem Cells .....	81
	Evaluation of Purging Technique .....	84
<b>3.4</b>	<b>Marrow Processing and Cryopreservation</b> .....	<b>86</b>
	<i>Michele Cottler-Fox</i>	
	Introduction .....	86
	Marrow Transport .....	86
	Volume Reduction of Marrow .....	86
	Red Blood Cell Depletion.....	88
	Buffy Coat Preparations .....	88
	Mononuclear Cell Separation .....	89
	Cryopreservation .....	90
	Thawing and Infusion .....	91
	Product Assessment/Quality Assurance .....	91
<b>4.0</b>	<b>Cytoreduction</b>	
<b>4.1</b>	<b>Conditioning (Preparative) Regimens</b> .....	<b>94</b>
	<i>Richard K. Burt, Wyndham H. Wilson</i>	
	General Principles .....	94
	Conditioning Regimens .....	95
	Specific Diseases .....	99
	Toxicity of Conditioning Agents.....	104
	Dose and Method of Administration .....	107
<b>4.2</b>	<b>Total Body Irradiation</b> .....	<b>109</b>
	<i>Shalina Gupta-Burt, Paul G. Okunieff</i>	
	Introduction .....	109
	Definitions .....	109

Normal Tissue Radiosensitivity .....	110
Hematopoietic Cell Radiosensitivity .....	110
Lymphocyte Radiosensitivity-Immunosuppression .....	111
Leukemia Cell Radiosensitivity .....	112
TBI Techniques .....	113
Toxicities After Accidental Exposure to Radiation .....	115
Toxicity After TBI and HSC Rescue .....	115
Pre-TBI Evaluation .....	121
Followup Guidelines .....	122
<b>4.3 High-Dose Alkylating Agent Pharmacology/Toxicity .....</b>	<b>123</b>
<i>William P. Petros, Colleen J. Gilbert</i>	
Rationale .....	123
Dose Selection .....	123
Mechanisms of Action of Alkylating Agents .....	123
Toxicologic Considerations .....	123
Pharmacokinetics .....	127
Administration Issues .....	128
Pontential Drug Interactions/Contraindications .....	129
<b>5.0 MHC and Bone Marrow Transplantation .....</b>	<b>132</b>
<i>Nancy Hensel</i>	
Definition and Classification of MHC .....	132
Structure of HLA Molecules .....	133
Laboratory Methods .....	133
HLA Nomenclature .....	136
HLA Genetics .....	140
Reporting of HLA Typing Data .....	140
Problems in Identifying HLA Genotypically Identical Siblings .....	143
Implications of HLA Matching for BMT .....	148
<b>6.0 Diseases</b>	
<b>6.1 Aplastic Anemia .....</b>	<b>154</b>
<i>Richard K. Burt, H. Joachim Deeg</i>	
Etiology .....	154
Diagnosis .....	154
Workup of Aplastic Anemia .....	154
Prognosis .....	155
Treatment Considerations .....	155
Immunosuppressive Therapy .....	156
Syngeneic Bone Marrow Transplantation .....	156
HLA Genotypically Identical Sibling BMT .....	158
BMT from Unrelated and Related Mismatched Donors .....	161
Autologous BMT .....	161
<b>6.2 Acute Myeloid Leukemia—AML .....</b>	<b>162</b>
<i>Richard K. Burt, Philip Rowlings, George W. Santos</i>	
Etiology .....	162
Diagnosis .....	162
Pretreatment Evaluation .....	162
Prognostic Factors .....	162
Treatment Philosophy .....	165
Chemotherapy .....	165
Allogeneic BMT .....	166
Autologous BMT .....	168
Syngeneic BMT .....	169

Unrelated or Mismatched BMT .....	170
Treatment of AML by Disease Stage .....	170
CNS Treatment .....	171
<b>6.3 Adult Acute Lymphoblastic Leukemia .....</b>	<b>173</b>
<i>Richard K. Burt, Philip Rowlings, George W. Santos</i>	
Etiology .....	173
Diagnosis .....	173
Childhood Versus Adult ALL .....	173
Pretreatment Evaluations .....	175
Prognosis .....	175
Treatment Philosophy .....	177
Chemotherapy .....	177
Allogeneic BMT .....	177
Autologous BMT .....	181
Syngeneic BMT .....	183
Unrelated BMT .....	183
Treatment of Adult ALL by Disease Stage .....	183
Prophylaxis of the CNS in Adult ALL .....	185
Treatment of Active CNS Disease .....	187
Treatment of the Testes .....	187
<b>6.4 Chronic Myeloid Leukemia—CML .....</b>	<b>188</b>
<i>Richard K. Burt, Philip Rowlings, George W. Santos</i>	
Etiology .....	188
Diagnosis .....	188
Workup of CML .....	189
Prognosis .....	189
Treatment Philosophy .....	189
Hydroxyurea, Busulfan .....	189
Interferon $\alpha$ .....	190
Genotypically Matched Sibling BMT .....	190
Autologous BMT .....	191
Unrelated BMT .....	191
<b>6.5 Chronic Lymphocytic Leukemia .....</b>	<b>193</b>
<i>Issa Khouri, Richard Champlin</i>	
Incidence and Etiology .....	193
Cytogenetics and Pathology .....	193
Diagnosis .....	193
Staging .....	193
Prognosis .....	194
Clinical Course .....	194
Differential Diagnosis .....	195
Indications for Initiating Therapy .....	195
Criteria for Remission in CLL .....	195
Treatment Options .....	197
<b>6.6 Multiple Myeloma .....</b>	<b>199</b>
<i>David H. Vesole, Ann E. Traynor, Sundar Jagannath, Guido Tricot, Bart Barlogie</i>	
Etiology .....	199
Epidemiology .....	199
Diagnosis .....	199
Staging System and Prognostic Factors .....	202
Pretreatment Evaluation .....	203

Treatment of Newly Diagnosed Myeloma .....	203
Therapy for Previously Treated Myeloma .....	204
Transplantation .....	206
<b>6.7 Bone Marrow Transplantation in Lymphomas .....</b>	<b>210</b>
<i>S. Martin-Algarra, Philip J. Bierman, James O. Armitage</i>	
Introduction .....	210
Etiology .....	210
Epidemiology .....	211
Classification .....	212
Staging and Prognostic Factors at Diagnosis .....	212
Natural History, Standard Therapy and Results with BMT .....	217
Pretransplant Staging .....	225
Conditioning Regimens .....	225
Stem Cell Source .....	227
Growth Factors .....	230
Therapy After Transplantation .....	231
Treatment of Lymphoma Relapse After BMT .....	231
Followup and Late Complications .....	231
<b>6.8 Adult Solid Tumors .....</b>	<b>235</b>
<i>Mary C. Territo, Michael C. Lill</i>	
Introduction .....	235
Breast Cancer .....	235
Testicular Cancer and Other Germ Cell Tumors .....	242
Epithelial Ovarian Cancer .....	247
Lung Cancer .....	250
<b>6.9 Bone Marrow Transplantation for Pediatric Malignancy .....</b>	<b>253</b>
<i>Robert A. Krance, Helen E. Heslop, Malcolm K. Brenner</i>	
Introduction .....	253
Childhood Acute Lymphoblastic Leukemia (ALL) .....	254
Childhood Acute Myeloid Leukemia (AML) .....	256
JCML/Myelodysplasia .....	256
Chronic Myeloid Leukemia (CML) .....	257
Neuroblastoma .....	257
Rhabdomyosarcoma .....	261
Ewing Sarcoma .....	263
Glioblastoma Multiforme .....	265
Other Brain Tumors .....	266
Other Tumors .....	266
<b>6.10 Hereditary Disorders of the Immune System Treatable by Bone Marrow Transplantation .....</b>	<b>267</b>
<i>Richard E. Harris, Cynthia DeLaat, Lisa Filipovich</i>	
Introduction .....	267
Severe Combined Immune Deficiency and Variants .....	267
Wiskott-Aldrich Syndrome (WAS) .....	270
Hemophagocytic Lymphohistiocytosis (HLH) .....	270
X-Linked Lymphoproliferative Syndrome (XLP) .....	271
Chediak-Higashi Syndrome (CHS) .....	272
Kostmann's Agranulocytosis .....	272
Chronic Granulomatous Disease (CGD) .....	272
CD11/18 Deficiency (Leukocyte Adhesion Deficiency) .....	273

<b>6.11</b>	<b>Lysosomal and Peroxisomal Storage Diseases</b> .....	<b>274</b>
	<i>Richard E. Harris, Nancy Leslie, William Krivit</i>	
	Introduction .....	274
	Etiology .....	275
	Diagnosis .....	275
	Pretreatment Evaluation .....	275
	Treatment Philosophy .....	276
	Conditioning Regimen and GVHD Prophylaxis .....	276
	Hurler Syndrome .....	276
	Hunter Syndrome .....	279
	Sanfilippo Syndrome .....	280
	Maroteaux-Lamy Syndrome (MLS) .....	281
	Gaucher Disease .....	280
	Metachromatic Leukodystrophy (MLD) .....	281
	Adrenoleukodystrophy (ALD) .....	281
	Globoid Cell Leukodystrophy (GLD) .....	283
	Other Miscellaneous Syndromes .....	283
	Cord Blood Transplantation .....	283
	Gene Therapy .....	283
<b>6.12</b>	<b>The Clinical Management of Thalassemia Patients Undergoing Bone Marrow Transplantation</b> .....	<b>286</b>
	<i>Emanuele Angelucci, Guido Lucarelli</i>	
	Introduction .....	286
	Definition of Thalassemia .....	286
	Treatment of $\beta$ -Thalassemia Major (Cooley's Anemia) .....	286
	Pretransplant Evaluation .....	288
	Bone Marrow Transplant for Thalassemia .....	292
	Posttransplant Followup .....	294
<b>6.13</b>	<b>Bone Marrow Transplantation for Sickle Cell Anemia</b> .....	<b>295</b>
	<i>Christopher L. Morris</i>	
	Introduction .....	295
	Nontransplant Therapy .....	295
	Bone Marrow Transplantation .....	295
	Pretransplant Evaluation .....	297
	Preparative Therapy .....	297
	Care of the Patient After Transplant .....	297
<b>7.0</b>	<b>Engraftment</b>	
<b>7.1</b>	<b>Approaches to Evaluation of Chimerism and Clonality</b> .....	<b>301</b>
	<i>Peter A. McSweeney</i>	
	Introduction .....	301
	Indications for Evaluating Chimerism .....	301
	Evaluation of Chimerism .....	301
	Interpretation of Chimerism Testing .....	305
	Evaluation of Clonality: X-Linked Clonal Analysis .....	306
<b>7.2</b>	<b>Graft Failure</b> .....	<b>309</b>
	<i>H. Joachim Deeg</i>	
	Introduction .....	309
	Definition of Graft Failure .....	309
	Risk and Prevention of Graft Failure .....	312
	Treatment of Graft Failure .....	314



<b>7.3 Minimal Residual Disease .....</b>	<b>317</b>
<i>F. Marc Stewart</i>	
Definition of Minimal Residual Disease (MRD) .....	317
Techniques to Assess Minimal Residual Disease .....	317
Application of Techniques to Detect Minimal Residual Disease ....	320
Significance of Minimal Residual Disease .....	320
Mixed Chimerism .....	324
Therapeutic Intervention for MRD After Stem Cell Transplantation in the Treatment of Hematologic Diseases .....	324
MRD in the Marrow and Purging .....	325
<b>7.4 Relapse After Bone Marrow Transplantation .....</b>	<b>326</b>
<i>F. Marc Stewart</i>	
Spectrum of Relapse .....	326
Treatment Approaches for Relapse After Bone Marrow Transplantation .....	326
<b>8.0 General Medical Care</b>	
<b>8.1 Diagnosis and Management of Complications Related to Long-Term Venous Access Devices .....</b>	<b>333</b>
<i>H. Richard Alexander</i>	
Introduction .....	333
Long-Term Venous Access Catheters .....	333
Pheresis Catheters .....	335
PICC Lines .....	336
Persistent Withdrawal Occlusion (PWO)—Inability to Aspirate .....	336
Partial Catheter Occlusion .....	337
Complete Catheter Occlusion—Inability to Infuse .....	338
Diagnosis and Management of Long-Term Access-Associated Infectious Complications .....	338
Catheter-Related Venous Thrombosis .....	342
Repair of a Catheter Fracture .....	342
Catheter Removal .....	342
<b>8.2 Nutritional Support in Bone Marrow Transplant Recipients ..</b>	<b>343</b>
<i>Sara L. Bergerson</i>	
Introduction .....	343
Calorie Requirements .....	343
Protein Requirements .....	343
Fluid Requirements .....	344
Diet .....	345
Parenteral Nutrition (PN) .....	345
Tube Feeding .....	347
Posttransplant Complications Affecting Nutritional Status .....	354
Out-Patient Nutritional Management .....	355
<b>8.3 Management of Pain in the Bone Marrow Transplant Patient .....</b>	<b>357</b>
<i>F. Peter Buckley</i>	
Introduction .....	357
Anatomy, Physiology and Pharmacology of Nociception .....	357
Monitoring Pain and Treatment Efficacy .....	358
Cognitive Behavior Techniques of Pain Relief .....	359
Physical Methods of Pain Control .....	360
Nonsteroidal Anti-inflammatory Drugs (NSAID) .....	360

Tricyclic Antidepressants (TCA) for Pain Control .....	362
Opioids for Pain Control .....	362
Local Anesthetics for Pain Control .....	373
Invasive Pain Control Techniques .....	374
Commonly Occurring Pain Problems in the BMT Patient .....	374
Pain from Diagnostic or Therapeutic Procedures .....	378
<b>8.4 Cardiovascular Support .....</b>	<b>380</b>
<i>Robert W. Taylor, Steven J. Trottier</i>	
Introduction .....	380
Prognosis .....	380
Fluids and Weight .....	380
Classification of Shock .....	380
Determinants of Cardiac Function .....	382
Pulmonary Artery Catheter .....	383
Pulmonary Artery Catheter Waveforms .....	386
Pulmonary Artery Catheter Measurements .....	386
Pulmonary Artery Catheter Complications .....	389
Arterial Pressure Monitoring .....	389
Arterial Catheter Waveform Analysis .....	390
Arterial Catheter Complications .....	390
Pharmacologic Support of the Cardiovascular System .....	390
<b>8.5 Respiratory Support .....</b>	<b>396</b>
<i>Steven J. Trottier, Robert W. Taylor</i>	
Definition of Respiratory Failure .....	396
Risk of Respiratory Failure in BMT .....	396
Causes of Respiratory Failure After BMT .....	396
Prognosis of Respiratory Failure in Patient's Undergoing Marrow Transplant .....	396
Oxygen Therapy .....	396
Airway Management .....	399
Mechanical Ventilation .....	400
Pharmacologic Support of the Respiratory System .....	404
<b>8.6 Disorders of Renal Function and Electrolytes .....</b>	<b>408</b>
<i>Bruce Kaplan, Salim Mujais</i>	
Acute Renal Failure .....	408
Sodium .....	411
Potassium .....	413
Calcium .....	416
Acid Base Balance .....	418
Metabolic Acidosis .....	418
Metabolic Alkalosis .....	419
Respiratory Alkalosis .....	419
Respiratory Acidosis .....	419
Renal Replacement Modalities .....	419
Cyclosporine (CsA) .....	420
Drug Dosing in Renal Impairment .....	421
<b>9.0 Growth Factors .....</b>	<b>424</b>
<i>Lori A. S. Hollis, Carole B. Miller</i>	
Introduction .....	424
Filgrastim (Human Granulocyte-Colony Stimulating Factor, G-CSF) .....	424

Sargramostim (Human Granulocyte-Macrophage Colony Stimulating Factor, GM-CSF) .....	427
Epoietin (Recombinant Human Erythropoietin, rHuEPO) .....	430
Other Cytokines Under Development or in Trials for Bone Marrow Transplantation .....	432
<b>10.0 Infections</b>	
<b>10.1 Infection Prophylaxis in Bone Marrow Transplant Recipients—Myths, Legends and Microbes</b> .....	<b>438</b>
<i>Richard K. Burt, Thomas J. Walsh</i>	
Risk for Infection .....	438
Source of Organisms .....	440
Temporal Sequence of Infections .....	442
Prevention of Infection .....	443
Surveillance Cultures .....	446
Immunoglobulins .....	448
Active Immunization .....	448
Fever/Neutropenia .....	449
Pneumocystis/Tuberculosis Prophylaxis .....	450
<b>10.2 Approaches to Management of Invasive Fungal Infections in Bone Marrow Transplant Recipients</b> .....	<b>452</b>
<i>Thomas J. Walsh, Philip A. Pizzo</i>	
Introduction .....	452
Deficits in Host Defense Predisposing BMT Recipients to Invasive Fungal Infections .....	452
Candidiasis .....	452
Aspergillosis .....	456
Emerging Opportunistic Fungi in Immunocompromised BMT Recipients .....	460
Recombinant Human Cytokines in the Management of Fungal Infections in BMT Recipients .....	462
Systemically Administered Antifungal Compounds in Bone Marrow Transplantation .....	462
<b>10.3 Virus Infections Complicating Bone Marrow Transplantation</b> .....	<b>469</b>
<i>William H. Burns</i>	
Introduction .....	469
Herpes Simplex Virus (HSV) .....	469
Cytomegalovirus (CMV) .....	470
Varicella Zoster Virus (VZV) .....	474
Enteroviruses .....	475
Respiratory Viruses .....	475
Epstein-Barr Virus .....	476
<b>11.0 Graft-Versus-Host Disease</b> .....	<b>478</b>
<i>Nelson J. Chao</i>	
Acute Graft-Versus-Host Disease (aGVHD) .....	478
Chronic Graft-Versus-Host Disease .....	490
Graft-Versus-Host Disease in Unrelated Donor BMT .....	497

<b>12.0</b>	<b>Graft-Versus-Leukemia Effect of Allogeneic BMT</b> .....	<b>499</b>
	<i>Dimitrios A. Mavroudis</i>	
	Introduction .....	499
	GVL Effect Associated with GVHD .....	499
	Loss of GVL with T Cell Depletion .....	499
	GVL of Allogeneic Versus Syngeneic Transplantation .....	500
	GVL Associated with Donor Leukocyte Infusions .....	500
	GVL Effect Associated with Cyclosporine Withdrawal .....	501
	Conclusion from Clinical Data .....	501
	Mechanisms of GVL .....	501
	Summary .....	502
<b>13.0</b>	<b>Toxicity</b>	
<b>13.1</b>	<b>Regimen Related Toxicity—First 30 Days</b>	
	<b>Early Toxicity of High Dose Therapy</b> .....	<b>504</b>
	<i>Gwynn D. Long</i>	
	Introduction .....	504
	Cardiac Toxicity .....	504
	Hepatic Toxicity-VOD .....	507
	Gastrointestinal Toxicity .....	509
	Pulmonary Toxicity .....	510
	Hemorrhagic Cystitis .....	511
	Renal Toxicity .....	512
	Central Nervous System Toxicity .....	512
	Skin Toxicity .....	513
<b>13.2</b>	<b>Delayed Complications</b> .....	<b>515</b>
	<i>H. Joachim Deeg</i>	
	Etiology of Delayed Complications .....	515
	Airway and Pulmonary Disease .....	515
	Autoimmune Dysfunction .....	518
	Neuroendocrine Dysfunction .....	518
	Ophthalmologic Problems .....	519
	Avascular Necrosis of the Bone .....	519
	Dental Problems .....	520
	Genitourinary Dysfunction .....	520
	Posttransplant Malignancies .....	520
	Central and Peripheral Nervous System .....	521
	Psychosocial Effects and Rehabilitation .....	521
<b>14.0</b>	<b>Outpatient Management of Marrow and Blood Stem Cell Transplant Patients</b> .....	<b>524</b>
	<i>Philip Gold, Mary E.D. Flowers, Keith M. Sullivan</i>	
	Introduction to the Outpatient Department .....	524
	Outpatient Monitoring .....	525
	Departure Home .....	527
	Long-Term Followup .....	528
	Immunizations .....	530
<b>15.0</b>	<b>Gene Therapy</b> .....	<b>533</b>
	<i>Christopher E. Walsh</i>	
	Introduction .....	533
	Hematopoietic Target Cells .....	533
	Methods of Gene Transfer .....	535

Clinical Applications .....	540
FDA/RAC Approval .....	542
Glossary of Terms .....	542
<b>16.0 Medications .....</b>	<b>544</b>
<i>Dominic A. Solimando</i>	
Antidiarrheal .....	544
Antiemetics .....	546
AntiFungal .....	549
Antihistamines (H <sub>2</sub> Antagonists) .....	551
Antimicrobials .....	551
Antimucositis Drugs .....	553
Antituberculosis Drugs .....	553
Antiviral .....	555
Hormonal Therapy .....	556
Chemotherapy .....	557
Diuretics .....	560
Electrolytes .....	561
Growth Factors/Biologic Response Modifiers .....	561
Uroprotectants .....	562
Immunizations .....	562
Intravenous Immunoglobulin (IVIG) .....	563
Immunosuppressive Agents .....	564
Veno-occlusive Disease .....	566

## Appendices

<b>I) Organizations Relevant to Bone Marrow Transplantation .....</b>	<b>568</b>
Related Allogeneic Data Registry .....	568
Autologous Data Registry .....	568
Unrelated Donor Registry .....	568
Physician BMT Organizations .....	573
Patient BMT Information .....	573
BMT Financial Support .....	574
Cancer Information .....	574
Leukemia Information .....	575
Aplastic Anemia / Fanconi's Anemia Information .....	575
Immunodeficiency Information .....	575
Insurance Information .....	575
<b>II) Allogeneic BMT Patient Pre-admission Evaluation .....</b>	<b>576</b>
<b>III) Leukocyte Antigens .....</b>	<b>578</b>
<b>IV) NCI Common Toxicity Criteria .....</b>	<b>584</b>
<b>V) Nomogram for Adult Body Surface Area .....</b>	<b>588</b>
<b>VI) Karnofsky and Lansky Play Performance Scales .....</b>	<b>589</b>
<b>VII) American Heart Association Life Support Algorithms .....</b>	<b>590</b>

# List of Tables

Table 1.2.1. Criteria for the performance of bone marrow transplantation from the American Society of Hematology and American Society of Clinical Oncology .....	9
Table 1.3.1. Karnofsky and ECOG Performance Status Scale .....	16
Table 1.3.2. Pretreatment testing and evaluation schedules .....	19
Table 1.4.1. Graft-versus-host disease, graft failure and disease-free survival for transplants with sibling matched or alternate donors .....	27
Table 1.5.1. Allogeneic bone marrow transplantation costs in adult acute myelogenous leukemia (in US dollars) .....	31
Table 1.5.2. Allogeneic bone marrow transplantation costs in severe aplastic anemia (in US dollars) .....	32
Table 1.5.3. Allogeneic bone marrow transplantation costs in chronic granulocytic leukemia (in US dollars) .....	32
Table 1.5.4. Approximate adult BMT charges per item (in dollars) .....	35
Table 2.1. Bone marrow harvest operative note .....	48
Table 2.2. Post bone marrow harvest orders .....	48
Table 3.1.1. Blood components .....	55
Table 3.1.2. Transfusion reactions .....	56
Table 3.1.3. Selection of recipient PRBC, platelets and plasma after allogeneic BMT .....	56
Table 3.1.4. Donor/recipient ABO incompatibility .....	57
Table 3.2.1. Average relative frequencies of cell types in an autologous graft .....	70
Table 3.2.2. Relative fold increase in autologous CFU-C collected by apheresis utilizing different mobilization strategies .....	71
Table 3.2.3. Methods used either alone or in combination to enrich for hematopoietic progenitor cells via positive or negative cell selection .....	73
Table 3.3.1. Purging methods for autologous bone marrow and peripheral stem cells .....	77
Table 3.3.2. Purging methods for allogeneic bone marrow and peripheral stem cells .....	82
Table 3.4.1. Standard marrow component processing .....	87
Table 4.1.1. Examples of some cyclophosphamide plus total body irradiation (CY/TBI) regimens .....	95
Table 4.1.2. Examples of busulfan-based regimens .....	96
Table 4.1.3. Examples of some noncyclophosphamide single agent chemotherapy plus total body irradiation regimens .....	97
Table 4.1.4. Examples of BACT-derived regimens .....	98
Table 4.1.5. Examples of solid tumor conditioning regimens .....	99
Table 4.1.6. Examples of some conditioning regimens for specific diseases .....	100
Table 4.1.7. Toxicity of some conditioning regimen drugs .....	105

Table 4.2.1. Large field irradiation-definitions .....	110
Table 4.2.2. Most commonly employed TBI regimens .....	110
Table 4.2.3. Whole organ irradiation normal tissue tolerance .....	111
Table 4.2.4. Effect of dose, dose fractionation and dose rate on clinical parameters important in bone marrow transplantation .....	112
Table 4.2.5. TBI-acute toxicities .....	116
Table 4.2.6. TBI chronic toxicities .....	118
Table 4.3.1. Pharmacologic principles of high-dose chemotherapy .....	124
Table 4.3.2. Dose-limiting toxicity of selected chemotherapeutic agents .....	124
Table 4.3.3. Relatively common adverse effects of individual high-dose drugs ..	125
Table 4.3.4. Pharmacokinetic issues of particular importance in high-dose chemotherapy .....	127
Table 4.3.5. Plasma half-life and primary excretion route for typical drugs used in high-dose regimens .....	128
Table 4.3.6. Drugs which may interact with ablative regimens .....	129
Table 5.1. Examples of HLA nomenclature .....	137
Table 5.2. Examples of high frequency public epitopes .....	138
Table 5.3. Cross-reactive groups .....	138
Table 5.4. Broad splits and associated antigens .....	139
Table 5.5. HLA-DR, DQ,Dw and Db1 associations .....	141
Table 5.6. Examples of allele frequencies in diverse populations .....	142
Table 5.7. Restriction of certain alleles in different populations .....	142
Table 5.8. Restriction of haplotypes to certain populations .....	142
Table 5.9. HLA polymorphism .....	143
Table 5.10. Complete listing of recognized HLA specificities .....	144
Table 6.1.1. Etiology of aplastic anemia .....	155
Table 6.1.2. Severe aplastic anemia (SAA) .....	155
Table 6.1.3. Bone marrow transplantation versus immunosuppressive therapy for severe aplastic anemia .....	157
Table 6.1.4. Immunosuppressive regimens for SAA .....	158
Table 6.1.5. ATG (anti-thymocyte globulin) desensitization protocol .....	159
Table 6.2.1. FAB classification of acute leukemias .....	163
Table 6.2.2. Correlation of French-American-British (FAB) subtype of acute myelogenous leukemia with immunophenotype .....	163
Table 6.2.3. Percent leukemia-free survival (LFS) and relapse (R) in AML .....	164
Table 6.2.4. AML regimens .....	165
Table 6.3.1. Distinguishing features of lymphoid (ALL) and myeloid (AML) blasts .....	174
Table 6.3.2. FAB histology of ALL .....	174
Table 6.3.3. Childhood Versus Adult ALL .....	175
Table 6.3.4a. Hoelzer adult ALL regimen (Blood 1988; 71 (1):123-131) .....	178

Table 6.3.4b. Linker adult ALL regimen (Blood 1991; 7(11):2814-2822) .....	179
Table 6.3.4c. Adult ALL MOAD regimen (Leukemia 1993; 7(8):1236-1241) .....	180
Table 6.3.4d. VAAP adult ALL regimen—short intensive treatment (Eur J Haematol 1988; 41: 489-495) .....	180
Table 6.3.5. Examples of salvage chemotherapy for adult ALL .....	185
Table 6.3.6. Intralumbar dose of chemotherapy by patient age .....	186
Table 6.5.1. Staging for CLL—Rai system .....	194
Table 6.5.2. Staging for CLL—the revised Rai system .....	194
Table 6.5.3. Staging for CLL—Binet system .....	194
Table 6.5.4. Staging for CLL—integrated system .....	194
Table 6.5.5. Mature B cell leukemia .....	196
Table 6.5.6. Remission criteria for CLL—comparison of the International Workshop on CLL (IWCLL) and the National Cancer Institute Sponsored Working Group for CLL (NCISWG) .....	196
Table 6.5.7. Examples of chemotherapy for chronic lymphocytic leukemia .....	197
Table 7.1.1. Comparisons of markers used to assay chimerism .....	302
Table 7.1.2. VNTR markers used for PCR-based chimerism analysis .....	304
Table 7.1.3. Interpretation of peripheral blood chimerism testing— likely diagnosis .....	306
Table 7.1.4. X-linked markers used for molecular analysis of clonality .....	307
Table 7.2.1. Potential sources of marrow or stem cells .....	310
Table 7.2.2. Causes of graft failure .....	310
Table 7.2.3. Documentation of donor cell engraftment and persistence/re-emergence of host cells .....	311
Table 7.2.4. Probability of graft failure with unmanipulated marrow grafts .....	313
Table 7.2.5. Prevention of graft failure .....	315
Table 7.3.1. Minimal residual disease in marrow or blood .....	318
Table 7.3.2. Chromosome aberrations and malignancies .....	321
Table 7.4.1. Clinical efficacy of donor leukocyte infusions for leukemia relapse after allogeneic bone marrow transplant .....	328
Table 8.1.1. Thrombolytic therapy of central venous catheter occlusion .....	337
Table 8.1.2. Commonly used criteria for the diagnosis of catheter-related bacteremia .....	339
Table 8.1.3. Thrombolytic therapy of catheter-related central vein thrombosis .....	340
Table 8.1.4. Catheter care guidelines .....	341
Table 8.2.1. Adjusted ideal body weight .....	344
Table 8.2.2. Estimation of calorie and protein needs .....	344
Table 8.2.3. Maintenance fluid needs .....	344
Table 8.2.4. Modified bacteria diet for BMT patients .....	346
Table 8.2.5. Process for approaching parenteral nutrition administration .....	347



Table 8.2.6. Suggested parenteral nutrition progression schedule .....	348
Table 8.2.7. Parenteral micronutrient requirement summary .....	349
Table 8.2.8. Guide for formulating parenteral nutrition in BMT patients .....	350
Table 8.2.9. Suggested monitoring parameters for PN .....	351
Table 8.2.10. Eating problems and suggested interventions .....	351
Table 8.2.11. Examples of enteral tube feeding formulas .....	352
Table 8.2.12. Gastrointestinal GVHD nutrition plan .....	355
Table 8.3.1. Dosing data for nonopioid analgesics .....	361
Table 8.3.2a. Opiate receptor effects .....	363
Table 8.3.2b. Opiate receptor interactions .....	363
Table 8.3.3. Dose equivalents for opioid analgesics .....	366
Table 8.4.1. Hemodynamic variables in various shock states .....	381
Table 8.4.2. Guideline for use of continuous infusion medication .....	391
Table 8.5.1. Causes of respiratory failure .....	397
Table 8.5.2. Mechanical ventilation .....	402
Table 8.5.3. Mechanical ventilation initial settings .....	405
Table 8.5.4. Weaning parameters .....	406
Table 8.5.5. Respiratory pharmacology agents .....	406
Table 8.6.1. Hyponatremia etiology .....	411
Table 8.6.2. Causes of hyperkalemia .....	414
Table 8.6.3. Hyperkalemia/urine tests indicative of a tubular defect in potassium secretion .....	414
Table 8.6.4. Treatment of hyperkalemia with EKG changes .....	415
Table 8.6.5. Compensation of acid base disorders .....	418
Table 8.6.6. Causes of metabolic acidosis and alkalosis .....	419
Table 8.6.7. Methods of monitoring CsA levels .....	421
Table 8.6.8. Drugs altering CsA levels .....	421
Table 8.6.9. Common drugs in BMT that need dosage adjustment .....	422
Table 9.1. Cellular effects of cytokines .....	426
Table 9.2. Growth factor dose .....	428
Table 9.3. Cytokine application in bone marrow transplantation .....	433
Table 10.1.1. T Cell reconstitution after allogeneic BMT .....	439
Table 10.1.2. B cell reconstitution after allogeneic BMT .....	440
Table 10.1.3. Mouth care .....	441
Table 10.1.4. Relationship between time of BMT and organisms causing common medically important infections .....	443
Table 10.1.5. Allogeneic BMT antimicrobial prophylaxis .....	445
Table 10.1.6. Examples of BMT gastrointestinal decontamination regimens .....	446
Table 10.1.7. Intravenous immunoglobulin (IVIG) .....	449

Table 10.1.8. Examples of empiric regimens for treatment of fever and neutropenia .....	450
Table 10.2.1. Common and emerging fungal pathogens in bone marrow transplant recipients .....	453
Table 10.2.2. Approaches to treatment of mucosal and invasive candidiasis in bone marrow transplant recipients .....	454
Table 10.2.3. Summary of approaches to treatment of fungal infections of the respiratory tract in bone marrow transplant recipients .....	457
Table 10.2.4. Reversal of immunosuppression: immunologic adjuncts to prevention and treatment of invasive fungal infections in bone marrow transplant recipients .....	462
Table 10.3.1a. Acyclovir dose for herpes simplex .....	471
Table 10.3.1b. Acyclovir dose for varicella zoster .....	471
Table 10.3.2a. Ganciclovir dose for pre-emptive therapy .....	474
Table 10.3.2b. Ganciclovir dose for treatment of CMV pneumonitis or enteritis .....	474
Table 10.3.3. Foscarnet dose .....	475
Table 11.1. Factors associated with lower acute GVHD .....	479
Table 11.2. Grading acute GVHD .....	482
Table 11.3. Two regimens for prophylaxis of acute GVHD .....	485
Table 11.4. Dose adjustment of cyclosporine and methotrexate .....	487
Table 11.5. Monoclonal antibody or receptor antagonist therapy for steroid-resistant acute GVHD .....	489
Table 11.6. Chronic GVHD grades .....	490
Table 12.1. GVL effect based on clinical data .....	500
Table 13.1.1. Regimen-related toxicity according to organ system .....	505
Table 13.1.2. Clinical criteria for veno-occlusive disease of the liver .....	507
Table 13.1.3. Tissue plasminogen activator and heparin for treatment of veno-occlusive disease of the liver (Fred Hutchinson Cancer Center protocol) .....	508
Table 13.2.1. Delayed complications .....	516
Table 14.1. Criteria for hospital discharge to the outpatient department .....	526
Table 14.2. Early complications of stem cell transplantation .....	527
Table 14.3. Criteria for hospital readmission .....	527
Table 14.4. Screening studies for chronic graft-versus-host disease .....	528
Table 14.5. Late complications of stem cell transplantation .....	528
Table 14.6. Recommended immunizations after hematopoietic transplantation .....	531
Table 15.1. Gene therapy .....	534
Table 15.2. Methods of gene transfer .....	536
Table 16.1. Emetic potential of chemotherapy agents .....	547

## EDITORS

**Richard K. Burt, M.D.**  
Northwestern University  
Chicago, Illinois, U.S.A.  
Chapters 4.1, 6.1, 6.2, 6.3, 6.4, 10.1

**H. Joachim Deeg, M.D.**  
Fred Hutchinson Cancer Center  
Seattle, Washington, U.S.A.  
Chapters 6.1, 7.2, 13.2

**Scott Thomas Lothian, R.Ph.**  
Northwestern Memorial Hospital  
Chicago, Illinois, U.S.A.

**George W. Santos, M.D.**  
Johns Hopkins University  
Baltimore, Maryland, U.S.A.  
Chapters 1.1, 6.2, 6.3, 6.4

## CONTRIBUTORS

H. Richard Alexander, M.D.  
Senior Investigator  
NIH, NCI, DCT, Surgery Branch  
Bethesda, Maryland, U.S.A.  
*Chapter 8.1*

S. Martin-Algarra, M.D.  
University of Nebraska Medical Center  
Department of Internal Medicine  
Section of Oncology/Hematology  
Omaha, Nebraska, U.S.A.  
*Chapter 6.7*

Emanuele Angelucci, M.D.  
Hematology Department  
Hospital of Pesaro  
Pesaro, Italy  
*Chapter 6.12*

Ellen Areman, M.S.  
Director, Technical Cellular  
Engineering Laboratory  
Georgetown University Hospital  
Washington, D.C., U.S.A.  
*Chapter 3.3*

James O. Armitage, M.D.  
Chief, Hematology Oncology  
University of Nebraska Medical Center  
Department of Internal Medicine  
Omaha, Nebraska, U.S.A.  
*Chapter 6.7*

Bart Barlogie, M.D., Ph.D.  
Professor of Medicine  
Chief, Hematology Oncology  
Arkansas Cancer Research Center  
University of Arkansas  
for Medical Sciences  
Little Rock, Arkansas, U.S.A.  
*Chapter 6.6*

Charles Bennett, M.D.  
Associate Professor of Medicine  
Northwestern University  
Medical School  
Senior Research Associate  
Lakeside VA Medical Center  
Chicago, Illinois, U.S.A.  
*Chapter 1.5*

Sara L. Bergerson, M.S., R.D., C.N.S.D.  
Clinical Nutrition Department  
NIH, Clinical Center  
Bethesda, Maryland, U.S.A.  
*Chapter 8.2*

Philip J. Bierman, M.D.  
University of Nebraska Medical Center  
Department of Internal Medicine  
Section of Oncology/Hematology  
Omaha, Nebraska, U.S.A.  
*Chapter 6.7*

Malcolm K. Brenner, M.D., Ph.D.  
Saint Jude Hospital  
Director, BMT Unit  
Memphis, Tennessee, U.S.A.  
*Chapter 6.9*

F. Peter Buckley, M.D.  
Medical Director, Pain and Toxicity  
Fred Hutchinson Cancer Center  
Seattle, Washington, U.S.A.  
*Chapter 8.3*

William H. Burns, M.D.  
Professor of Medicine  
Director, BMT Unit  
Medical College of Wisconsin  
Milwaukee, Wisconsin, U.S.A.  
*Chapter 10.3*

Shalina Gupta-Burt, M.D.  
Rush University  
Chicago, Illinois, U.S.A.  
*Chapter 4.2*

Richard Champlin, M.D.  
Director, BMT  
M.D. Anderson Cancer Center  
Houston, Texas, U.S.A.  
*Chapters 1.4, 6.5*

Nelson J. Chao, M.D.  
Assistant Director, BMT Unit  
Stanford University Hospital  
Stanford, California, U.S.A.  
*Chapter 11.0*

Cynthia DeLaat, M.D.  
Assistant Professor of Pediatrics  
Director of Late Effects Clinic  
Children's Hospital Medical Center  
Cincinnati, Ohio, U.S.A.  
*Chapter 6.10*

Suzanne G. Demko, P.A.C.  
Lead PA and Research Coordinator  
BMT Unit  
Johns Hopkins Hospital  
Baltimore, Maryland, U.S.A.  
*Chapter 2.0*

Lisa Filipovich, M.D.  
Professor of Pediatrics  
Director, Pediatric Immunology  
University of Minnesota  
Minneapolis, Minnesota, U.S.A.  
*Chapter 6.10*

Mary E.D. Flowers, M.D.  
The Fred Hutchinson Cancer  
Research Center  
University of Washington  
School of Medicine  
Seattle, Washington, U.S.A.  
*Chapter 14*

Michele Cottler-Fox, M.D.  
Medical Director  
Stem Cell Laboratory  
Marrow/Stem Cell Transplant Program  
University of Maryland Cancer Center  
Baltimore, Maryland, U.S.A.  
*Chapters 3.1, 3.2, 3.4*

James Gajewski, M.D.  
Section of BMT  
Department of Hematology  
MD Anderson Cancer Center  
Houston, Texas, U.S.A.  
*Chapter 1.4*

Colleen J. Gilbert, Pharm.D.  
BMT Program  
Duke University Medical Center  
Durham, North Carolina, U.S.A.  
*Chapter 4.3*

Philip Gold, M.D.  
The Fred Hutchinson Cancer  
Research Center  
University of Washington  
School of Medicine  
Seattle, Washington, U.S.A.  
*Chapter 14*

Richard E. Harris, M.D.  
Director, BMT  
University of Cincinnati  
Children's Hospital  
Cincinnati, Ohio, U.S.A.  
*Chapters 6.10, 6.11*

Nancy Hensel, M.T.(ASCP),  
C.H.S.(ABHI)  
National Institutes of Health  
National Heart, Lung  
and Blood Institute  
Bethesda, Maryland, U.S.A.  
*Chapter 5.0*

Helen E. Heslop, M.D.  
Saint Jude Hospital  
Director, BMT Unit  
Memphis, Tennessee, U.S.A.  
*Chapter 6.9*

Lori A.S. Hollis, Pharm.D.  
Johns Hopkins Oncology Center  
Baltimore, Maryland, U.S.A.  
*Chapter 9*

Sundar Jagannath, M.D.  
Professor of Medicine  
Division of Hematology/Oncology  
Chief of BMT  
Arkansas Cancer Research Center  
University of Arkansas  
for Medical Sciences  
Little Rock, Arkansas, U.S.A.  
*Chapter 6.6*

Bruce Kaplan, M.D.  
Division of Nephrology  
Northwestern University  
Chicago, Illinois, U.S.A.  
*Chapter 8.6*

Issa Khouri, M.D.  
M.D. Anderson Cancer Center  
Houston, Texas, U.S.A.  
*Chapter 6.5*

Robert A. Krance, M.D.  
Saint Jude Hospital  
Clinical Director, BMT Unit  
Memphis, Tennessee, U.S.A.  
*Chapter 6.9*

William Krivit, M.D., Ph.D.  
Professor of Pediatrics  
University of Minnesota  
Hospitals and Clinics  
Minneapolis, Minnesota, U.S.A.  
*Chapter 6.11*

Nancy Leslie, M.D.  
Assistant Professor of Pediatrics  
Head, Metabolic Services  
Division of Human Genetics  
Children's Hospital Medical Center  
Cincinnati, Ohio, U.S.A.  
*Chapter 6.11*

Michael C. Lill, M.D.  
UCLA, BMT Unit  
University of California  
School of Medicine  
Los Angeles, California, U.S.A.  
*Chapter 6.8*

Gwynn D. Long, M.D.  
Stanford University Hospital  
Stanford, California, U.S.A.  
*Chapter 13.1*

Guido Lucarelli, M.D.  
Hematology Department  
Hospital of Pesaro  
Pesaro, Italy  
*Chapter 6.12*

Dimitrios A. Mavroudis, M.D.  
Hematology-Oncology Fellow  
BMT Unit, NHLBI, NHI  
Bethesda, Maryland, U.S.A.  
*Chapter 12*

Philip L. McCarthy Jr., M.D.  
Director, Bone  
Marrow Transplant Program  
Baylor College of Medicine  
Methodist Hospital  
Houston, Texas, U.S.A.  
*Chapters 1.2, 1.3*

Peter A. McSweeney, M.D.  
Fred Hutchinson Cancer Center  
Seattle, Washington, U.S.A.  
*Chapter 7.1*

Carole B. Miller, M.D.  
Assistant Professor of Oncology  
Johns Hopkins University  
Baltimore, Maryland, U.S.A.  
*Chapter 9*

Christopher L. Morris, M.D., Ph.D.  
Marrow Transplant Program  
Children's Hospital Medical Center  
Cincinnati, Ohio, U.S.A.  
*Chapter 6.13*

Salim Mujais, M.D.  
Division of Nephrology  
Northwestern University  
Chicago, Illinois, U.S.A.  
*Chapter 8.6*

Paul G. Okunieff, M.D.  
Radiation Oncology Branch  
National Institutes of Health  
Bethesda, Maryland, U.S.A.  
*Chapter 4.2*

William P. Petros, Pharm.D.  
BMT Program  
Duke University Medical Center  
Durham, North Carolina, U.S.A.  
*Chapter 4.3*

Philip A. Pizzo, M.D.  
Infectious Diseases Section  
Pediatric Branch  
National Cancer Institute  
Bethesda, Maryland, U.S.A.  
*Chapter 10.2*

Chitra Rajagopal, M.D.  
BMT Program  
Georgetown University Medical Center  
Washington, D.C., U.S.A.  
*Chapter 3.3*

Philip Rowlings, M.D.  
International BMT Registry  
Milwaukee, Wisconsin, U.S.A.  
*Chapters 6.2, 6.3, 6.4*

Dominic A. Solimando Jr., M.A.  
Department of Pharmacy  
Thomas Jefferson University Hospital  
Philadelphia, Pennsylvania, U.S.A.  
*Chapter 16*

F. Marc Stewart, M.D.  
Chairman, Hematology/Oncology  
University of Massachusetts  
Worcester, Massachusetts, U.S.A.  
*Chapters 7.3, 7.4*

Keith M. Sullivan, M.D.  
Fred Hutchinson Cancer Center  
and University of Washington  
Seattle, Washington, U.S.A.  
*Chapter 14*

Robert W. Taylor, M.D.  
Director, Critical Care Unit  
Saint John's Mercy Hospital  
St. Louis, Missouri, U.S.A.  
*Chapters 8.4, 8.5*

Mary C. Territo, M.D.  
Director, UCLA BMT Unit  
University of California  
School of Medicine  
Los Angeles, California, U.S.A.  
*Chapter 6.8*

Ann E. Traynor, M.D.  
Division of Hematology/Oncology  
Northwestern University  
Chicago, Illinois, U.S.A.  
*Chapter 6.6*

Guido Tricot, M.D., Ph.D.  
Professor of Medicine  
Division of Hematology/Oncology  
Arkansas Cancer Research Center  
University of Arkansas  
for Medical Sciences  
Little Rock, Arkansas, U.S.A.  
*Chapter 6.6*

Steven J. Trottier, M.D.  
Clinical Assistant Professor  
St. Louis University  
School of Medicine  
Department of Critical Care Medicine  
St. John's Mercy Medical Center  
St. Louis, Missouri, U.S.A.  
*Chapters 8.4, 8.5*

David H. Vesole, M.D., Ph.D.  
Assistant Professor of Medicine  
Division of Hematology/Oncology  
Arkansas Cancer Research Center  
University of Arkansas  
for Medical Sciences  
Little Rock, Arkansas, U.S.A.  
*Chapter 6.6*

Christopher E. Walsh, M.D., Ph.D.  
Senior Investigator  
NIH, CC, CPD, Hematology Service  
Bethesda, Maryland, U.S.A.  
*Chapter 15*

Thomas J. Walsh, M.D.  
Senior Investigator  
Infectious Diseases Section  
Head, Mycology Unit  
NIH, NCI, DCT, Pediatric Branch  
Bethesda, Maryland, U.S.A.  
*Chapter 10.2*

Ilana Westerman, B.A.  
Northwestern University  
Chicago, Illinois, U.S.A.  
*Chapter 1.5*

Lori A. Williams, R.N.  
Clinical Nurse Specialist  
Oncology and BMT  
Georgetown University Hospital  
Washington, D.C., U.S.A.  
*Chapters 1.2, 1.3*

Wyndham H. Wilson, Ph.D., M.D.  
Special Assistant to the Director  
NIH, NCI, DCT  
Bethesda, Maryland, U.S.A.  
*Chapter 4.1*